Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 9/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856304 | 0.93 | KEAP1 (0.53) | CCR1KEAP1NFE2L2EPHX1KDM4E | |
| SCHEMBL2854462 | 0.92 | KEAP1 (0.48) | CCR1KEAP1NFE2L2EPHX1KDM4E | |
| SCHEMBL2853388 | 0.92 | CCR1 (0.48) | CCR1ABCB1KDM4EALDH1A1 | |
| SCHEMBL2860700 | 0.89 | KEAP1 (0.46) | CCR1KEAP1NFE2L2EPHX1KDM4E | |
| SCHEMBL2849956 | 0.89 | CCR1 (0.62) | CCR1 | |
| SCHEMBL2853253 | 0.89 | KEAP1 (0.42) | CCR1KEAP1NFE2L2EPHX1LIPG | |
| SCHEMBL2854543 | 0.88 | CCR1 (0.54) | CCR1ABCB1 | |
| SCHEMBL2853364 | 0.88 | CCR1 (0.52) | CCR1KEAP1NFE2L2EPHX1KDM4E | |
| SCHEMBL2856356 | 0.88 | ALDH1A1 (0.47) | CCR1ABCB1KDM4EALDH1A1 | |
| SCHEMBL2859076 | 0.86 | KEAP1 (0.42) | CCR1KEAP1NFE2L2EPHX1LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |